Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective
| Autor: | Kevin Bowrin, Anna-Katharina Meinecke, Jean-Baptiste Briere, Julie Dorey, Pierre Levy, Mondher Toumi, David M. Smadja |
|---|---|
| Přispěvatelé: | Laboratoire d'Economie de Dauphine (LEDa), Institut de Recherche pour le Développement (IRD)-Université Paris Dauphine-PSL, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS), INSERM, l'Institut national de la santé et de la recherche médicale (INSERM), Ministère de la Santé et de la Recherche, Laboratoire de Santé Publique, Université de la Méditerranée - Aix-Marseille 2, Pharmaco-Epidémiologie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Non valvular atrial fibrillation international normalised ratio lcsh:Business 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Internal medicine Societal perspective real-world research medicine resource use and costs In patient Original Research Article cardiovascular diseases 030212 general & internal medicine health care economics and organizations [QFIN]Quantitative Finance [q-fin] business.industry lcsh:Public aspects of medicine Correction lcsh:RA1-1270 Atrial fibrillation Vitamin K antagonist medicine.disease 3. Good health JEL: I - Health Education and Welfare/I.I1 - Health/I.I1.I12 - Health Behavior vitamin K antagonists monitoring JEL: I - Health Education and Welfare/I.I1 - Health/I.I1.I11 - Analysis of Health Care Markets cardiovascular system Cardiology International normalised ratio Nonvalvular atrial fibrillation France lcsh:HF5001-6182 business |
| Zdroj: | Journal of Market Access & Health Policy Journal of Market Access & Health Policy, 2019, 7 (1), ⟨10.1080/20016689.2018.1564506⟩ Journal of Market Access & Health Policy, Vol 7, Iss 1 (2019) |
| Popis: | Background: Little is known about the costs associated with vitamin K antagonist (VKA) treatment in patients with non-valvular atrial fibrillation (NVAF) in France. Objectives: To evaluate monthly per-patient costs attributable to VKA treatment in NVAF patients from a French societal perspective. Study design: Retrospective data were obtained from 7 international normalised ratio (INR) monitoring centres in France. Patients older than 18 years of age with NVAF treated with VKA were recruited. Additional patient-level data assessing resource use corresponding with VKA treatment were collected via self-completed questionnaires. Unit costs applicable to 2015 were multiplied by resource use and summed to generate VKA treatment costs. Results: 363 patients were included; 53% were men. The majority of patients received fluindione (72%). The number of INR tests per patient per month was 1.69 (95% CI, 1.59–1.80). The monthly patient cost was €39.72 (€36.23–43.21) from the French societal perspective. Direct medical costs comprised 76% of overall costs, with drug costs representing 7.4% (€2.4); direct non-medical and indirect costs comprised 10% and 14% respectively. Conclusions: Costs associated with VKA treatment in NVAF cannot be estimated only with drug costs. When direct and indirect attributable costs associated with VKA treatment are considered, the VKA treatment costs are more substantial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|